ELECTROSURGICAL DEVICES MARKET ANALYSIS

Key Developments

• On January 24, 2024, Olympus Corporation, a global medical technology business, announced the full market availability of its new ESG-410 Surgical Energy Platform for conventional monopolar and bipolar, advanced energy applications such as ultrasonic dissection, and hybrid energy. The ESG-410 Surgical Energy Platform provides a comprehensive energy solution with applications in a variety of disciplines, including general surgery, thoracic surgery, urology, and gynecology.
• In April 2023, Innoblative Designs, Inc., a private medical device company that addresses clinical unmet needs for breast cancer patients, announced that its SIRA RFA Electrosurgical Device (SIRA) has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA). The SIRA device is intended for use in breast cancer patients undergoing BCS, often known as lumpectomy.
• In October 2022, ZEISS Medical Technology, a healthcare technology company, announced that MTLawton has been granted 510(k) approval by the U.S. FDA. These new disposable bipolar forceps, composed of a unique copper-base alloy, have the potential to minimize tissue adhesion and consequent charring during tissue dissection. The forceps' longer shaft reduces sight limits in the surgical field, allowing surgeons to be more efficient during electrosurgical treatments.
• In September 2022, US Medical Innovations, LLC (USMI), a subsidiary of US Patent Innovations, LLC, a private biomedical technology firm, announced that it has secured a USD 10.2 million private placement agreement from a variety of sources, including current partners and new investors. USMI plans to use these funds to increase production of its recently announced Canady Plasma XL-1000 SMART Electrosurgical Generator (XL-1000), as well as to support the development and release of its Canady Helios Cold Plasma Generator (CHCP) and robotic delivery system for cancer therapy.